Not Tagged
Not Tagged
['brca', 'cspc', 'crpc', 'prostate', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'cspc ']
now at #gu23 (abstract # 81), we present on the survival benefit of fda-approved therapies for metastatic prostate cancer between 2004-2022. there were 14 approvals (single or combination) during this time period. most (81.3%) drugs received regular approval. (1/3) 
Physician and researcher with interests in genitourinary cancers and health policy. Tweets are my own views, and are not medical advice.